Physician profile
Clay E Stalcup
NPI 1750389979
$6,280.83
in general payments reported to CMS, 2019-2025
37 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $703 · 2021: $800 · 2022: $776 · 2023: $838 · 2024: $1,200 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.73 |
| Education | $140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $944.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $806.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $735.37 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $466.35 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $334.82 | 2024-2025 | Auvelity |
| Pfizer INC. | $302.62 | 2019-2025 | |
| Astellas Pharma US INC | $291.57 | 2022-2024 | Veozah |
| Allergan, INC. | $225.84 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.79 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $208.95 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.66 | 2020-2023 | Ofev, Spiriva Respimat, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $175.81 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $173.28 | 2021-2025 | Gvoke Hypopen |
| Amgen INC. | $162.22 | 2019-2022 | |
| Lilly USA, LLC | $119.57 | 2022-2025 | Mounjaro, Zepbound |
Show all 36 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Stalcup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.